New Algorithm Proposes Targeted Lipase Monitoring for Pancreatic Adverse Events In Melanoma
Source: Dermatology Times, November 2024
Researchers recommend limiting routine lipase tests to symptomatic patients or those with radiographic signs of pancreatic injury.
A recent international, multicenter study published in the Journal of the European Academy of Dermatology and Venereology shed light on immune checkpoint inhibitor-induced pancreatic injury (ICIPI), a lesser-understood adverse effect associated with immune checkpoint inhibitors (ICIs) used in melanoma treatment.
The study, involving 1,516 patients across multiple centers in Austria and Switzerland, provides insights into the incidence, management, and outcomes of ICIPI. Despite its low occurrence rate (0.5% to 3%), the condition can lead to complications, such as pancreatic insufficiency, particularly when undiagnosed in asymptomatic patients.